Stephen Willard, JD

Mr. Willard brings a wealth of experience in the management of publicly traded biotechnology companies, together with his background in law and finance. Most recently, Mr. Willard served as CEO of Cellphire Therapeutics, where he shepherded their revolutionary human platelet platform through key clinical trials, grew the company and significantly increased its share price. He previously served as CEO of publicly traded Flamel Technologies (now Avadel Pharmaceuticals). Mr. Willard is currently serving a presidential appointment to the National Science Board. Mr. Willard served as Associate Director of the Federal Deposit Insurance Corporation (FDIC), and on the board of E*Trade Financial Services from 2000-2014. He has practiced law in New York, London, and Washington, D.C. Mr. Willard earned his undergraduate degree from Williams College and attended Yale University where he earned a JD in law.